Philips has become aware that ResMed has issued an urgent field safety notice that described a statistically significant 2.5 percent absolute increased annual risk of cardiovascular mortality for those randomized to a ResMed Adaptive Servo Ventilation (ASV) Therapy compared to the control group. In the patient population with reduced Left Ventricular Ejection Fraction (LVEF = 45%), 10.0 percent of the ASV group experienced a cardiovascular death each year compared to 7.5 percent of the control group, representing a 33.5 percent relative increased risk of cardiovascular mortality (HR=1.335, 95%CI=(1.070, 1.666), P-value= 0.010).
Philips is actively evaluating the information provided by ResMed and examining if this might impact the medical care of patients who use the Philips devices listed above. Until Philips completes our investigation, based on the ResMed announcement, Philips is strongly recommending that clinicians adhere to the following recommendations:
Do not place new patients with symptomatic chronic heart failure (NYHA 2-4) and reduced LVEF=45%, and moderate to severe predominant central sleep apnea on ASV therapy. Before putting patients on ASV, each patient should be assessed for heart failure. in case of signs and symptoms of heart failure an objective assessment of LVEF should be performed. Current patients should be evaluated and a discussion about whether to discontinue ASV therapy should occur if a current patient is found to be in the at-risk population. If it is unknown whether a current patient falls within the at-risk population, the patient should be evaluated to determine if ASV therapy should continue.